24602-Oulu Vaccine Research Clinic
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kokko, Satu
NCT05371080 / 2021-005319-30: A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Active, not recruiting
3
3038
Europe, Canada, Japan, US, RoW
HZ/su vaccine
GlaxoSmithKline
Herpes Zoster
08/27
08/27
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
NCT06551181: A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

Recruiting
3
2600
Europe, Japan, RoW
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/25
09/25
NCT05705440 / 2022-003124-41: A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Completed
3
3962
Europe, Canada, US, RoW
RSVPreF3 vaccine, Control
GlaxoSmithKline, GlaxoSmithKline Biologicals SA
Respiratory Syncytial Virus Infections
01/25
01/25
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Active, not recruiting
3
35800
Europe, RoW
aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV
Seqirus
Influenza, Human
11/26
12/26
NCT05082285 / 2021-001367-24: A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Active, not recruiting
2
724
Europe, RoW
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, MenABCWY-1Gen vaccine, MenB vaccine, Bexsero, MenACWY-TT vaccine, Nimenrix
GlaxoSmithKline
Infections, Meningococcal
03/25
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kokko, Satu
NCT05371080 / 2021-005319-30: A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

Active, not recruiting
3
3038
Europe, Canada, Japan, US, RoW
HZ/su vaccine
GlaxoSmithKline
Herpes Zoster
08/27
08/27
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
NCT06551181: A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

Recruiting
3
2600
Europe, Japan, RoW
RSVPreF3 OA investigational vaccine, Placebo
GlaxoSmithKline
Respiratory Syncytial Virus Infections
03/25
09/25
NCT05705440 / 2022-003124-41: A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Completed
3
3962
Europe, Canada, US, RoW
RSVPreF3 vaccine, Control
GlaxoSmithKline, GlaxoSmithKline Biologicals SA
Respiratory Syncytial Virus Infections
01/25
01/25
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Active, not recruiting
3
35800
Europe, RoW
aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV
Seqirus
Influenza, Human
11/26
12/26
NCT05082285 / 2021-001367-24: A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Active, not recruiting
2
724
Europe, RoW
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, MenABCWY-1Gen vaccine, MenB vaccine, Bexsero, MenACWY-TT vaccine, Nimenrix
GlaxoSmithKline
Infections, Meningococcal
03/25
03/25

Download Options